(BRTX) BioRestorative Therapies, Inc. Business Model Canvas Research

Clinical research sites are key partners for BioRestorative Therapies, Inc. because BRTX-100 has already advanced through Phase 1 testing, which depends on investigators, patient enrollment, and protocol execution. These sites also produce the safety and feasibility data needed before later-stage trials, and each enrolled patient directly affects speed and cost efficiency.

• Enable Phase 1 enrollment and dosing
• Run protocol and safety checks
• Generate feasibility data for next phases

BioRestorative Therapies, Inc. depends on suppliers and manufacturing partners for lab support, cell processing, reagents, consumables, and device parts, because clinical-grade cell therapy needs tight control and repeatable batches. These relationships help keep quality, traceability, and reproducibility consistent across development and GMP-style production.

• Reagents and consumables keep batches consistent
• Device parts support controlled processing
• Manufacturing partners protect quality and traceability

BioRestorative Therapies, Inc. develops an investigational curved-needle spine delivery device designed to place cells and other therapeutic materials into the spine and discs. This work supports both product development and the procedures needed to use those therapies in practice.

• Investigational curved-needle design
• Targets spine and disc delivery
• Supports R&D and procedure enablement

As a clinical-stage Company, BioRestorative Therapies, Inc. focuses on regulatory planning, trial design, documentation, and safety reporting to keep its lead programs moving through development. The Company’s work centers on generating the scientific and medical evidence needed for 2 core programs, including BRTX-100, while aligning with FDA expectations at each step.

• 2 core development programs
• Trial design and safety reporting
• Evidence generation drives progress

BioRestorative Therapies, Inc. depends on stem cell processing and regenerative medicine know how to design protocols, read trial data, and protect proprietary methods. This scientific edge matters because its lead clinical work, BRTX-100, still hinges on precise cell handling and interpretation of human data.

• Stem cell processing expertise
• Protocol design and data readout
• Defends proprietary methods

BioRestorative Therapies, Inc. relies on 3 key external ties: Rohto, Pfizer, and the University of Pennsylvania. These partnerships add scientific validation, widen access to research talent, and support development work that BioRestorative Therapies, Inc. would be costly to build alone.

• 3 named strategic research links
• External validation from 2 global pharma names
• University of Pennsylvania adds academic expertise

BioRestorative Therapies, Inc. uses multiple regenerative platforms across spine disease and metabolic disorders, with lead programs BRTX-100 and BioReCell. That two-track model widens the therapy pipeline, creates more shots at clinical success, and lowers reliance on one indication.

• Spine plus metabolic exposure
• Two lead platforms, one company
• Less single-indication risk

BioRestorative Therapies, Inc.'s curved needle device is built to place cells and therapeutic materials into the spine more accurately, which can improve procedure precision and support better treatment delivery. That matters in a 2025 care setting where about 18,000 new spinal cord injury cases are reported in the U.S. each year, so tighter targeting adds real clinical value.

• Improves spinal delivery accuracy
• Supports cells and therapeutic materials
• Adds practical value to therapy workflow

BioRestorative Therapies, Inc., founded in 1997, needs steady investor updates because its value depends on trial progress, milestone timing, and cash runway. In a clinical-stage public company, clear communication helps support financing for its pipeline, especially when shareholders track dilution risk and development spend.

• Milestones drive share-price moves
• Trial updates reduce information gaps
• Cash runway shapes financing needs

This relationship is active, not passive: management must keep the market informed as programs advance, or investors will price in higher funding risk and slower execution.

BioRestorative Therapies, Inc. must keep clinicians aligned on how regenerative medicine works, what each study is testing, and where the risks sit. In 2025, the company was still in an R&D stage with no commercial product revenue, so clear medical updates are key to building trust with physicians, investigators, and payers.

• Explain mechanism in plain terms
• State trial phase and endpoints
• Disclose safety risks early
• Use data to support adoption

BioRestorative Therapies, Inc. uses its company website and investor relations page to post SEC filings, press releases, and pipeline updates, so shareholders can track material events fast. Public-company disclosures on these channels keep program status visible to a wider audience and support transparent access to financial and operating information.

• SEC filings and press releases
• Shareholder access to material facts
• Pipeline status for broader reach

BioRestorative Therapies, Inc. must reach spine specialists and metabolic disease stakeholders through direct outreach, meetings, and clinical education. These channels build trust, support referral paths, and can speed adoption when teams need clear evidence on safety, outcomes, and fit for patients.

• Spine specialists: target referral flow.

• Metabolic stakeholders: support awareness.

• Education: drive trial and adoption.

Hospitals and clinical research centers run the procedures, enroll patients, and collect the trial data BioRestorative Therapies, Inc. needs in the development phase. In 2025, BioRestorative Therapies, Inc. remained pre-revenue, so these sites are the core institutional customers now and the same network can support treatment delivery if approval comes.

• Run trials and patient procedures
• Provide regulated clinical data
• Anchor future delivery sites

BioRestorative Therapies, Inc. serves pharma, biotech, and academic partners because small regenerative medicine firms often need outside capital, lab capacity, and deal access. These partners can fund research, co-develop assets, or license technology, while also helping move candidates from early science to clinical work.

• Funding for research
• Co-development of assets
• Technology licensing

BioRestorative Therapies, Inc. carries legal overhead from patents, contracts, and collaboration deals, and this matters more when protecting its proprietary cell-therapy and device ideas. In its 2025 filing, the company still ran at a loss, so IP and legal spend is part of defending long-term value, not just admin cost.

• Patents protect core methods.
• Contracts add legal overhead.
• Defensibility supports pricing power.

BioRestorative Therapies, Inc. carries public-company overhead in general and administrative costs, mainly for management, finance, SEC reporting, legal, audit, and investor relations. These recurring listing costs are fixed cash drains, so they stay high even when product or clinical spending slows.

• Management and finance overhead
• SEC, audit, and legal fees
• Investor relations and listing costs

BioRestorative Therapies, Inc. could add a second revenue line with the curved needle device through direct sales or licensing fees, alongside its cell-therapy programs. In its latest 2025 filings, the company still had no product revenue, so even a small device launch or bundle could matter.

• Direct device sales or licensing
• Bundled with therapy programs
• Extra monetization beyond cell therapy

BioRestorative Therapies, Inc. can use research grants and other non dilutive funding to pay for early stage preclinical and translational work, which lowers cash burn before product sales scale. For a clinical stage biotech, this matters because it cuts reliance on dilutive equity and supports longer R&D runway.

• Funds preclinical studies
• Supports translational work
• Reduces dilution risk
• Extends cash runway